CLAIMS:

1. Crystalline 1-(((1(*R*)-(3-(2-(7-chloro-2-quinolinyl)ethenyl)-phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl) propyl)thio)methyl)cyclopropane acetic acid having characteristic X-ray powder diffraction peaks, designated by 2θ and expressed in degrees, at 6.5±0.2°, 10.0±0.2°, 15.5±0.2°, 18.3±0.2°, 20.4±0.2° and 24.6±0.2°.

2. The crystalline 1-(((1(*R*)-(3-(2-(7-chloro-2-quinolinyl)ethenyl)-phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl) propyl)thio)methyl)cyclopropane acetic acid according to claim 1, characterized by a monoclinic space group $P\,2_1$ and by displaying unit cell parameters comprising: crystal axis lengths of $a = 7.95 \pm 0.02$ Å, $b = 21.94 \pm 0.02$ Å, $c = 17.95 \pm 0.02$ Å and an angle between the crystal axes of $\beta = 100.0\ 3 \pm 0.02°$.

3. The crystalline 1-(((1(*R*)-(3-(2-(7-chloro-2-quinolinyl)ethenyl)-phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl) propyl)thio)methyl)cyclopropane acetic acid according to claim 1 or 2, characterized in that it is provided with a purity of greater than 90.0%, preferably greater than 95%, preferably greater than 99%, preferably greater than 99,9%.

4. A process for preparing the crystalline 1-(((1(*R*)-(3-(2-(7-chloro-2-quinolinyl)ethenyl)-phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl) propyl)thio)methyl)cyclopropane acetic acid according to any one of claims 1 to 3, comprising the steps

- dissolving a salt of 1-(((1(*R*)-(3-(2-(7-chloro-2-quinolinyl)ethenyl)-phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl) propyl)thio)methyl)cyclopropane acetic acid in a solution A comprising at least one organic solvent,
- converting the salt of 1-(((1(*R*)-(3-(2-(7-chloro-2-quinolinyl)ethenyl)-phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl) propyl)thio)methyl)cyclopropane acetic acid into acid,
- crystallizing the 1-(((1(*R*)-(3-(2-(7-chloro-2-quinolinyl)ethenyl)-phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl) propyl)thio)methyl)cyclopropane acetic acid, and
- optionally isolating the crystalline 1-(((1(*R*)-(3-(2-(7-chloro-2-quinolinyl)ethenyl)-phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl) propyl)thio)methyl)cyclopropane acetic acid.

5. The process according to claim 4, characterized in that the converting step is carried out with a solution B comprising at least one aqueous solution and a chromatographic column, respectively.

6. The process according to claim 5, characterized in that the dissolving step and converting step are carried out together in a mixture comprising solution A and solution B, preferably in a ratio solution B : solution A of 1:10 to 10:1.

7. A process according to claim 5, characterized in that the 1-(((1(*R*)-(3-(2-(7-chloro-2-quinolinyl)ethenyl)-phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl) propyl)thio)methyl)cyclopropane acetic acid is eluted from the column with the solution A comprising at least one organic solvent.

8. Amorphous form I of 1-(((1(*R*)-(3-(2-(7-chloro-2-quinolinyl)ethenyl)-phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl) propyl)thio)methyl)cyclopropane acetic acid having a characteristic DSC thermogram with two endothermic peaks, one at between 43°C and 53 °C, preferably between 47 °C and 49 °C, preferably at 48°C and one at between 143°C and 153 °C, preferably between 147 °C and 149 °C, preferably at 148°C and further having one exothermic peak at between 86 °C and 96 °C, preferably between 90 °C and 92 °C, preferably at 91°C.

9. A process for preparing the amorphous form I of 1-(((1(*R*)-(3-(2-(7-chloro-2-quinolinyl)ethenyl)-phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl) propyl)thio)methyl)cyclopropane acetic acid according to claim 8, comprising grinding the crystal form of 1-(((1(*R*)-(3-(2-(7-chloro-2-quinolinyl)ethenyl)-phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl) propyl)thio)methyl)cyclopropane acetic acid.

10. Amorphous form II of 1-(((1(*R*)-(3-(2-(7-chloro-2-quinolinyl)ethenyl)-phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl) propyl)thio)methyl)cyclopropane acetic acid having a characteristic DSC thermogram as shown in Fig. 9.

11. The process for preparing the amorphous form II of 1-(((1(*R*)-(3-(2-(7-chloro-2-quinolinyl)ethenyl)-phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl) propyl)thio)methyl)cyclopropane acetic acid according to claim 10, comprising

- providing a suspension of the crystal form of 1-(((1(*R*)-(3-(2-(7-chloro-2-quinolinyl)ethenyl)-phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl) propyl)thio)methyl)cyclopropane acetic acid, or a salt thereof, in an acidic aqueous solution and
- isolating said amorphous form II.

12. A pharmaceutical composition comprising the crystalline 1-(((1(*R*)-(3-(2-(7-chloro-2-quinolinyl)ethenyl)-phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio) methyl) cyclopropane acetic acid according to any one of claims 1 to 3, the amorphous form I according to claim 8, and/or the amorphous form II according to claim 10, and one or more pharmaceutically acceptable carriers or excipients.

13. Crystalline 1-(((1(*R*)-(3-(2-(7-chloro-2-quinolinyl)ethenyl)-phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl) cyclopropane acetic acid according to any one of claims 1 to 3, the amorphous form I according to claim 8, and/or the amorphous form II according to claim 10, for the use of treating asthma in a human.